Table 1.
Characteristics of Patients With Stage III Colon Cancer
| Characteristic | No. of Patients (N = 34,694) (%)* |
|---|---|
| Receipt of adjuvant chemotherapy | |
| No | 8,422 (24.3) |
| Yes | 26,272 (75.7) |
| Age at diagnosis, years | |
| 18-50 | 6,018 (17.4) |
| 51-64 | 12,441 (35.9) |
| 65-70 | 6,324 (18.2) |
| 71-75 | 5,104 (14.7) |
| 76-80 | 4,807 (13.9) |
| Race/ethnicity | |
| Non-Hispanic white | 23,815 (68.6) |
| Hispanic | 1,954 (5.6) |
| Black | 5,053 (14.6) |
| Other | 1,424 (4.1) |
| Unknown | 2,448 (7.1) |
| Sex | |
| Male | 17,488 (50.4) |
| Female | 17,206 (49.6) |
| Insurance | |
| Uninsured | 1,709 (4.9) |
| Medicaid | 1,963 (5.7) |
| Medicare (age 18-64 years) | 1,566 (4.5) |
| Medicare with supplement | 8,140 (23.5) |
| Medicare without supplement | 2,627 (7.6) |
| Medicare Advantage | 1,600 (4.6) |
| Medicare/Medicaid | 979 (2.8) |
| Private | 15,578 (44.9) |
| Missing | 532 (1.5) |
| Diagnosis year | |
| 2007 | 8,826 (25.4) |
| 2008 | 8,911 (25.7) |
| 2009 | 8,486 (24.5) |
| 2010 | 8,471 (24.4) |
| Median income level | |
| < $30,000 | 5,178 (14.9) |
| $30,000-$34,999 | 6,572 (18.9) |
| $35,000-$45,999 | 9,710 (28.0) |
| ≥ $46,000 | 12,750 (36.8) |
| Missing | 484 (1.4) |
| Facility type | |
| Community cancer program† | 5,184 (14.9) |
| Comprehensive community cancer program‡ | 17,296 (49.9) |
| Teaching/research center§ | 6,676 (19.2) |
| NCI program/network‖ | 2,023 (5.8) |
| Other¶ | 3,515 (10.1) |
| Charlson-Deyo comorbidity score# | |
| 0 | 24,288 (70.0) |
| 1 | 7,285 (21.0) |
| 2+ | 3,121 (9.0) |
| Travel distance, miles | |
| 0-12.49 | 18,563 (53.5) |
| 12.5-49.9 | 12,748 (36.7) |
| 50-249 | 3,026 (8.7) |
| ≥ 250 | 357 (1.0) |
| Density level of medical oncologist | |
| High | 2,479 (7.2) |
| Low | 32,215 (92.9) |
| No. of positive lymph nodes | |
| < 4 | 21,913 (63.2) |
| ≥ 4 | 12,641 (36.4) |
| Unknown | 140 (0.4) |
| Tumor grade | |
| Well differentiated | 2,135 (6.2) |
| Moderately differentiated | 22,996 (66.3) |
| Poorly differentiated | 7,933 (22.9) |
| Undifferentiated | 804 (2.3) |
| Unknown | 826 (2.4) |
| Surgical margin | |
| Negative | 31,502 (90.8) |
| Positive | 2,708 (7.8) |
| Unknown | 484 (1.4) |
Abbreviation: NCI, National Cancer Institute.
Because of rounding, percentages presented throughout this table may not add up to precisely 100%.
Facilities report 101 to 499 patients with newly diagnosed cancer each year. A full range of diagnostic and treatment services is provided, but referral for a portion of diagnosis or treatment may occur.
Facilities report ≥ 500 patients with newly diagnosed cancer each year. A full range of diagnostic and treatment services is provided either on site or by referral.
Facilities report ≥ 500 patients with newly diagnosed cancer each year and provide postgraduate medical education in at least four program areas. A full range of diagnostic and treatment services is provided either on site or by referral.
Facilities are designated a comprehensive cancer center by the NCI, with an NCI peer-reviewed cancer center support grant. A full range of diagnostic and treatment services is provided. No minimum caseload is required.
Facilities that are accredited as Integrated Network Cancer Program, Hospital Associate Cancer Program, or Free-Standing Cancer Center Program. Integrated Network Cancer Program is for facilities that are owned or operated by multiple facilities providing integrated cancer care. Hospital Associate Cancer Program is for facilities that report ≤ 100 patients with newly diagnosed cancer each year with limited range of diagnostic and treatment services. Free-Standing Cancer Center Program is for non–hospital-based facilities that offer at least one cancer-related treatment.
Charlson-Deyo comorbidity score is a weighted score evaluating severe comorbidities that increase the risk of 1-year mortality. Fifteen noncancer comorbid conditions were identified and weighted to calculate Charlson-Deyo comorbidity scores.